In this study, we investigated the inhibitory properties of TCM (C1) and TTM (C2 and C3) in two types of PLC, HCC and CCA, in vitro. Standard chemotherapeutics which are currently used in the clinic (sorafenib for HCC and gemcitabine for CCA) were used as positive controls. Here, HSPG2 is linked to cholangiocarcinoma.